LUCENCE

In partnership with

Parkway Laboratories

Standard-of-Care Tissue Profiling

Targeted panel for swift results

Standard40 Tissue NGS (Lung, Colon And Solid Tumors) is a next-generation sequencing (NGS) test identifying targeted somatic genomic alterations in 40 genes using DNA and RNA isolated from tumor tissue with results in up to 7 working days.

This aids in identification of multiple disease alterations for which FDA/HSA approved and CDL-covered treatments are available, with support for identification of available clinical trials.

The test covers all actionable targets for lung (9 guideline-recommended targets) and colon (*NRAS, KRAS, BRAF, ERBB2, NTRK*).

Targets list

Genes

AKT1	*CDKN2A #*	*FGFR1*	*GNAQ*	*KIT*	*MTOR*	*PIK3CA #*	*SMO*
ALK #	*CTNNB1*	*FGFR2*	*GNAS*	*KRAS #*	*NRAS*	*PTEN #*	*TP53*
AR #	*EGFR #*	*FGFR3*	*HRAS*	*MAP2K1*	*NTRK1*	*RAF1*	
ARAF	*ERBB2 #*	*FLT3*	*IDH1*	*MAP2K2*	*NTRK3*	*RET*	
BRAF	*ESR1*	*GNA11*	*IDH2*	*MET #*	*PDGFRA*	*ROS1*	

#: Includes detection of gene copy number changes.

Fusions & Splice variants

ALK	*EGFR*	*FGFR1*	*FGFR3*	*NRG1*	*NTRK2*	*NUTM1*	*ROS1*
BRAF	*ESR1*	*FGFR2*	*MET*	*NTRK1*	*NTRK3*	*RET*	

Test Specifications[1]

Methodology	Ultra-deep next-generation sequencing
Biomarkers analyzed	SNVs, Indels, CNVs, Fusions & Splice variants
Sample type	FFPE tumor tissue
Turnaround time	Up to 7 working days

	Sensitivity	**Specificity**
SNVs/Indels	98%	100%
Fusions	91.25%	100%

- Results tested at the stated mutant allele frequencies using reference standards, FFPE cell line samples, and FFPE clinical samples.
- Sensitivity and specificity reported for SNVs and Indels are at 5% VAF.

References:
[1] Ng, CC-Y. et al. Front. Mol. Biosci. 2022. 9:963243.

This test is facilitated through Parkway Labs | Contact to order: 6933 0801/6248 5807 | sgapadmin@parkwaypantai.com

Lucence Service Laboratory 211 Henderson Road #04-02, Henderson Industrial Park, Singapore 159552 lucence.com

M3019E-SG-01. January 2024